Similar Search Results

Management of Rheumatoid Arthritis: Defining the Role of Leflunomide

Carswell, Christopher I.; Perry, Caroline M.; Ibbotson, Tim - In: Disease Management and Health Outcomes 11 (2003) 11, pp. 745-765

methotrexate. In addition, leflunomide has been shown to be a cost effective option compared with etanercept, infliximab and … infliximab plus methotrexate. Leflunomide was generally well tolerated in clinical trials. Common adverse events associated with … arthritis, leflunomide had a more rapid onset of action than methotrexate, sulfasalazine and placebo. In trials of 24 months …

Persistent link: https://www.econbiz.de/10005590103

Rheumatoid Arthritis: Diagnosis and Screening

Leeb, Burkhard F.; Weber, Katharina; Smolen, Josef S. - In: Disease Management and Health Outcomes 4 (1998) 6, pp. 315-324

Rheumatoid arthritis is a common inflammatory joint disorder, with a prevalence of about 1% in the general population. It shows high variability with respect to its course and prognosis. In typical cases an insidious onset of symmetrical synovitis of the small joints of the hands and feet...

Persistent link: https://www.econbiz.de/10005590148

Choice of NSAID and Management Strategy in Rheumatoid Arthritis and Osteoarthritis: The Impact on Costs and Outcomes in the UK

McCabe, Chris J.; Akehurst, Ron L.; Kirsch, Jeff; … - In: PharmacoEconomics 14 (1998) 2, pp. 191-199

Objective: Although nonsteroidal anti-inflammatory drugs (NSAIDs) are an effective therapy for rheumatoid arthritis, they are associated with significant adverse effects, the management of which imposes additional costs on the healthcare system. Prescribing NSAIDs which have a lower risk of...

Persistent link: https://www.econbiz.de/10005590543

International Variation in Resource Utilisation and Treatment Costs for Rheumatoid Arthritis: A Systematic Literature Review

Rosery, Hubertus; Bergemann, Rito; Maxion-Bergemann, … - In: PharmacoEconomics 23 (2005) 3, pp. 243-257

Recent years have witnessed substantial progress in understanding the cost implications of rheumatoid arthritis (RA). To assess the divergent methodologies and their impact on the resulting cost analyses in RA, we conducted a systematic literature review to summarise the scientific evidence of...

Persistent link: https://www.econbiz.de/10005590545

Costs and Benefits of Prevention and Disease Management

Musich, Shirley A.; Burton, Wayne N.; Edington, Dee W. - In: Disease Management and Health Outcomes 5 (1999) 3, pp. 153-166

Prevention and long term disease management have been added relatively recently as `new' components of a modern day total healthcare services system. The goal of primary prevention, which includes medical preventive services, lifestyle interventions and screening services, is to maintain a...

Persistent link: https://www.econbiz.de/10004990302

Diclofenac/Misoprostol: Pharmacoeconomic Implications of Therapy

Plosker, Greg L.; Lamb, Harriet M. - In: PharmacoEconomics 16 (1999) 1, pp. 85-98

_ The combined formulation of diclofenac/misoprostol provides effective relief of pain and inflammation, with a 2- to 3-fold lower incidence of NSAID-associated gastroduodenal ulcers than diclofenac monotherapy. _ Both components of the combined formulation have been widely used and have well...

Persistent link: https://www.econbiz.de/10004990336

Sociodemographic Differences in Quality of Life in Rheumatoid Arthritis

Groessl, Erik J.; Ganiats, Theodore G.; Sarkin, Andrew J. - In: PharmacoEconomics 24 (2006) 2, pp. 109-121

Assessment of health-related quality of life (HR-QOL) in people with rheumatoid arthritis (RA) has become important in health research and can inform clinical care. Many studies have found sociodemographic differences in the HR-QOL of people with RA, and interpreting these differences can be...

Persistent link: https://www.econbiz.de/10004990356

Cost Effectiveness of Prostacyclins in Pulmonary Arterial Hypertension

Roman, Antonio; Barberà, Joan A. Barber; Escribano, Pilar - In: Applied Health Economics and Health Policy 10 (2012) 3, pp. 175-188

Background:Background: Pulmonary arterial hypertension (PAH) is considered an orphan disease. Prostacyclins are the keystone for PAH treatment. Choosing between the three available prostacyclin therapies could be complicated because there are no comparison studies, so the final decision must be...

Persistent link: https://www.econbiz.de/10011005061

Cost-Effectiveness Analysis of Early versus Non-Early Intervention in Acute Migraine Based on Evidence from the 'Act when Mild' Study

Slof, John - In: Applied Health Economics and Health Policy 10 (2012) 3, pp. 201-215

Background:Background: In spite of the important progress made in the abortive treatment of acute migraine episodes since the introduction of triptans, reduction of pain and associated symptoms is in many cases still not as effective nor as fast as would be desirable. Recent research pays more...

Persistent link: https://www.econbiz.de/10011005063

Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium

Hiligsmann, Mickal; Reginster, Jean-Yves - In: PharmacoEconomics 29 (2011) 10, pp. 895-911

Background: Denosumab has recently been shown to be well tolerated, to increase bone mineral density (BMD) and to significantly reduce the risk of hip, vertebral and non-vertebral fractures in the FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial. It is...

Persistent link: https://www.econbiz.de/10011005074